Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes

Mesher, David; Soldan, Kate; Lehtinen, Matti; Beddows, Simon; Brisson, Marc; Brotherton, Julia M.L.; Chow, Eric P.F.; Cummings, Teresa; Drolet, Mélanie; Fairley, Christopher K.; Garland, Suzanne M.; Kahn, Jessica A.; Kavanagh, Kimberley; Markowitz, Lauri; Pollock, Kevin G.; Söderlund-Strand, Anna; Sonnenberg, Pam; Tabrizi, Sepehr N.; Tanton, Clare; Unger, Elizabeth; Thomas, Sara L.

doi:10.3201/eid2210.160675

Back to Previous Page

- Add this to...
- Twitter
- Facebook
- Google Bookmarks
- LinkedIn

Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes

Published Date:

Oct 2016

Publisher's site:

http://dx.doi.org/10.3201/eid2210.160675 New Site Icon

Source:

Emerg Infect Dis. 22(10):1732-1740.

[PDF-964.03 KB]

Details:

Personal Authors:

Mesher, David ; Soldan, Kate ; Lehtinen, Matti ; Beddows, Simon ; Brisson, Marc ; ... More ▼

Keywords:

[+]

Pubmed ID:

27648688

Pubmed Central ID:

PMC5038419

Description:

We analyzed human papillomavirus (HPV) prevalences during prevaccination and postvaccination periods to consider possible changes in nonvaccine HPV genotypes after introduction of vaccines that confer protection against 2 high-risk types, HPV16 and HPV18. Our meta-analysis included 9 studies with data for 13,886 girls and women ≤19 years of age and 23,340 women 20-24 years of age. We found evidence of cross-protection for HPV31 among the younger age group after vaccine introduction but little evidence for reductions of HPV33 and HPV45. For the group this same age group, we also found slight increases in 2 nonvaccine high-risk HPV types (HPV39 and HPV52) and in 2 possible high-risk types (HPV53 and HPV73). However, results between age groups and vaccines used were inconsistent, and the increases had possible alternative explanations; consequently, these data provided no clear evidence for type replacement. Continued monitoring of these HPV genotypes is important.

Document Type:

Journal Article

Collection(s):

Emerging Infectious Diseases

Funding:

R01 AI073713/AI/NIAID NIH HHS/United States
R01 AI104709/AI/NIAID NIH HHS/United States

Supporting Files:

	16-0675-F1.gif	image/gif
	16-0675-F1.jpg	image/jpeg
	16-0675-F2.gif	image/gif
	16-0675-F2.jpg	image/jpeg
	16-0675-F3.gif	image/gif
	16-0675-F3.jpg	image/jpeg
	16-0675-Techapp-s1.pdf	application/pdf
	16-0675.nxml	application/octet-stream

No Related Documents.

You May Also Like:

Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009–2013

Personal Author:

Cameron, Ross L.; Kavanagh, Kimberley; Pan, Jiafeng; Love, John; Cuschieri, Kate; Robertson, Chris; Ahmed, Syed; Palmer, Timothy; Pollock, Kevin G.J.;

Published:

Jan 2016

Source:

Emerg Infect Dis. 22(1):56-64.

Description:

In 2008, a national human papillomavirus (HPV) immunization program using a bivalent vaccine against HPV types 16 and 18 was implemented in Scotland along with a national surveillance program designed to determine the longitudinal effects of vaccinat...

File Type:

[PDF - 527.22 KB]
Human papillomavirus vaccination : recommendations of the Advisory Committee on Immunization Practices (ACIP)

Personal Author:

Markowitz, Lauri E.; Dunne, Eileen F.; Saraiya, Mona; Chesson, Harrell W.; Curtis, C. Robinette; Gee, Julianne; Bocchini, Joseph A.; Unger, Elizabeth R., 1951-;

Corporate Author:

United States. Advisory Committee on Immunization Practices.; National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (U.S.). Division of STD Prevention.;

Published:

August 29, 2014

Source:

MMWR Recomm Rep. 2014 Aug 29;63(RR-05):1-30.

Series:

MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports ; v. 63, RR-05

Description:

This report summarizes the epidemiology of human papillomavirus (HPV) and associated diseases, describes the licensed HPV vaccines, provides updated data from clinical trials and postlicensure safety studies, and compiles recommendations from CDC's A...

Status:

current

File Type:

[PDF - 757.82 KB]
Prevalence of Human Papillomavirus Among Females After Vaccine Introduction—National Health and Nutrition Examination Survey, United States, 2003–2014

Personal Author:

Oliver, Sara E.; Unger, Elizabeth R.; Lewis, Rayleen; McDaniel, Darius; Gargano, Julia W.; Steinau, Martin; Markowitz, Lauri E.;

Published:

Sep 01 2017

Source:

J Infect Dis. 216(5):594-603.

Description:

Background : Human papillomavirus (HPV) vaccine was recommended in 2006 for routine vaccination of US females aged 11–12 years. Most vaccine used through 2014 was quadrivalent vaccine (4vHPV), which prevents HPV-6, -11, -16, and -18 infection. To e...

File Type:

[PDF - 506.86 KB]
Deadly River: Cholera and Cover-Up in Post-Earthquake Haiti

Personal Author:

Morris, J. Glenn

Published:

Nov 2016

Source:

Emerg Infect Dis. 22(11):2029-2030.

File Type:

[PDF - 680.91 KB]
HPV genotypes detected in cervical cancers from Alaska Native women, 1980–2007

Personal Author:

Kelly, Janet J.; Unger, Elizabeth R.; Dunne, Eileen F.; Murphy, Neil J.; Tiesinga, James; Koller, Kathy R.; Swango-Wilson, Amy; Philemonof, Dino; Lounmala, Xay; Markowitz, Lauri E.; Steinau, Martin; Hennessy, Thomas;

Published:

Aug 05 2013

Source:

Int J Circumpolar Health. 2013; 72.

Description:

Background : Human papillomavirus (HPV) vaccine prevents cervical pre-cancers and cancers caused by HPV types 16 and 18. This study provides information on the HPV types detected in cervical cancers of Alaska Native (AN) women. : Methods : Cases of i...

File Type:

[PDF - 77.77 KB]